{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:38:43Z","timestamp":1788385123103,"version":"build-2803163510"},"reference-count":31,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive neoplasms with poor outcomes, commonly affecting older patients with comorbidities. This study aims to describe outcomes of older patients with PTCL in a large international cohort. Patients aged \u226570 years with PTCL diagnosed from 1 January 2010 to 31 December 2015 in the Swedish Lymphoma Registry (SLR) and California Cancer Registry (CCR) were identified. Data on comorbidity were retrospectively collected according to the Charlson Comorbidity Index (CCI), and clinical outcomes were extracted. A total of 891 patients were included (SLR, n = 173; CCR, n = 718). Median age was 77 (SLR) and 78 (CCR) years. Included subtypes were as follows: angioimmunoblastic T-cell lymphoma, n = 226; anaplastic large-cell lymphoma, n = 122; enteropathy-associated T-cell lymphoma (EATL), n = 31; hepatosplenic TCL, n = 7; natural killer\u2013\/T-cell lymphoma, n = 62; PTCL not otherwise specified, n = 443. CCI data were available in 775 patients (87%), and CCI scores were divided into the groups CCI = 0 (39%), CCI = 1 (22%), and CCI &amp;gt; 1 (39%). Median age did not differ among the CCI groups (P = .72). Patients with a CCI &amp;gt; 1 had a worse median overall survival (4.4 months) compared with patients with CCI = 0 (11.9 months) and CCI = 1 (8.4 months; P &amp;lt; .001). Comorbidity and advancing age in as little as 5-year increments are important adverse factors in this group. Most patients died of lymphoma within a year from diagnosis, underscoring the importance of developing new treatments.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004269","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T16:32:32Z","timestamp":1632760352000},"page":"2120-2128","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients"],"prefix":"10.1182","volume":"6","author":[{"given":"Monica","family":"Mead","sequence":"first","affiliation":[{"name":"Department of Medicine\/Division of Hematology and Oncology, UCLA Medical Center, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0728-1549","authenticated-orcid":false,"given":"Henrik","family":"Cederleuf","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Hematology and Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Bj\u00f6rklund","sequence":"additional","affiliation":[{"name":"Department of Medicine, Skane University Hospital, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, UCLA Medical Center, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Relander","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Lund University, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Hematology and Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Gaut","sequence":"additional","affiliation":[{"name":"Department of Medicine, UCLA Medical Center, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Hematology and Oncology, UCLA Medical Center, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Ellin","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Hematology and Oncology, and"},{"name":"Kalmar County Hospital, Kalmar, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"issue":"25","key":"2022033015293235800_B1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol."},{"issue":"20","key":"2022033015293235800_B2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"issue":"10","key":"2022033015293235800_B3","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol."},{"issue":"10","key":"2022033015293235800_B4","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood."},{"issue":"17","key":"2022033015293235800_B5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood."},{"issue":"13","key":"2022033015293235800_B6","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer."},{"issue":"6","key":"2022033015293235800_B7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.rpor.2016.07.009","article-title":"Low dose palliative radiotherapy for refractory aggressive lymphoma","volume":"21","author":"Tanaka","year":"2016","journal-title":"Rep Pract Oncol Radiother."},{"key":"2022033015293235800_B8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hon.2413","article-title":"Management of aggressive lymphoma in very elderly patients","volume":"35","author":"Thieblemont","year":"2017","journal-title":"Hematol Oncol."},{"issue":"9","key":"2022033015293235800_B9","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States","volume":"34","author":"Adams","year":"2016","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022033015293235800_B10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjh.12765","article-title":"Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study","volume":"165","author":"Wieringa","year":"2014","journal-title":"Br J Haematol."},{"issue":"5","key":"2022033015293235800_B11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis."},{"issue":"4","key":"2022033015293235800_B12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00277-016-2597-y","article-title":"Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK)","volume":"95","author":"Jo","year":"2016","journal-title":"Ann Hematol."},{"issue":"2","key":"2022033015293235800_B13","first-page":"438","article-title":"[Analysis of clinical characteristics and prognosis of 46 elderly patients with peripheral T cell lymphoma (PTCL)]","volume":"24","author":"Wang","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi."},{"issue":"1","key":"2022033015293235800_B14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/hon.2428","article-title":"Impact of comorbidity on survival in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study","volume":"36","author":"Ellin","year":"2018","journal-title":"Hematol Oncol."},{"issue":"10","key":"2022033015293235800_B15","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3109\/10428194.2011.587560","article-title":"Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry","volume":"52","author":"Abrahamsson","year":"2011","journal-title":"Leuk Lymphoma."},{"issue":"25","key":"2022033015293235800_B16","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol."},{"key":"2022033015293235800_B17","first-page":"1795","article-title":"Comorbidity as an independent prognostic factor in elderly patients with peripheral T-cell lymphoma","volume":"9","author":"Zhao","year":"2016","journal-title":"OncoTargets Ther."},{"issue":"2","key":"2022033015293235800_B18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Adv."},{"issue":"9","key":"2022033015293235800_B19","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood."},{"issue":"3","key":"2022033015293235800_B20","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.15859","article-title":"Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas","volume":"186","author":"Ellin","year":"2019","journal-title":"Br J Haematol."},{"issue":"23","key":"2022033015293235800_B21","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022033015293235800_B22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol."},{"issue":"18","key":"2022033015293235800_B23","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol."},{"issue":"10168","key":"2022033015293235800_B24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet."},{"issue":"1","key":"2022033015293235800_B25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hon.2705","article-title":"Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials","volume":"38","author":"Ma","year":"2020","journal-title":"Hematol Oncol."},{"key":"2022033015293235800_B26","author":"Efficacy and safety"},{"key":"2022033015293235800_B27","author":"CC486-CHOP in patients with previously untreated peripheral T-cell lymphoma (NCT03542266)"},{"key":"2022033015293235800_B28","author":"Nivolumab with standard of care chemotherapy for peripheral T cell lymphomas (NCT03586999)"},{"key":"2022033015293235800_B29","author":"A study of duvelisib in patients with relapsed or refractory peripheral T cell lymphoma (PTCL) (NCT03372057)"},{"key":"2022033015293235800_B30","author":"Assessing AOJKI"},{"key":"2022033015293235800_B31","author":"Efficacy and safety of oral HBI-8000 in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) (NCT02953652)"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/7\/2120\/1884404\/advancesadv2021004269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/7\/2120\/1884404\/advancesadv2021004269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T20:03:43Z","timestamp":1648670623000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/7\/2120\/477033\/Impact-of-comorbidity-in-older-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,4,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004269","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]}}}